![](https://lymphoma.org/wp-content/uploads/2024/05/Subtypes-1.jpg.webp)
News
![](https://lymphoma.org/wp-content/uploads/2024/05/Subtypes-1.jpg.webp)
![](https://lymphoma.org/wp-content/uploads/2023/09/Rimsza2020-1-768x512.jpg)
Patient Perspectives: Understanding Diagnostic Testing
Read the Latest Issue of Pulse: Summer 2023
Dear Friends of LRF, It is a privilege to introduce you to the next generation of lymphoma researchers in this issue of Pulse, as we announce the 2023 class of the Lymphoma Research Foundation’s (LRF’s) Lymphoma Scientific Research Mentoring Program…
Where Are They Now? Mantle Cell Lymphoma Consortium and Initiative: 20 Years in Review
Where Are They Now? Mantle Cell Lymphoma Consortium and Initiative: 20 Years in Review Mantle cell lymphoma (MCL) is a rare, typically aggressive form of non-Hodgkin lymphoma (NHL) which accounts for roughly six percent of all NHL cases in the…
Finding Light In the Middle of the Woods
Finding Light In the Middle of the Woods Ilyse Leibowitz always dreamed of having a second home in the Berkshires. A former elementary school teacher and certified yoga instructor with a deep connection to nature and spirituality, she calls the…
A Dedication for Caring for Others
A Dedication for Caring for Others Ann S. LaCasce, MD, MMSc, an Associate Professor of Medicine at the Dana-Farber Cancer Institute, grew up in a healthcare-centered family. Her father was an internist in a small community in Maine, and as…
Lymphoma Research Foundation to Honor Esteemed Lymphoma Physician Kara Kelly, MD at Annual Gala on September 28
LRF Welcomes Scientific Advisory Board Chair Ann S. LaCasce, MD, MMSc
Lymphoma Research Foundation Announces Inaugural Recipient of the Annual Kanti R. Rai, MD Clinical Scholar Award
The U.S. Food and Drug Administration Approves Glofitamab-gxbm (Columvi) for Diffuse Large B-Cell Lymphoma
On June 15, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. “People with relapsed or…